tetano
Editor, Senior Moderator
PLoS One. 2017 Sep 14;12(9):e0183315. doi: 10.1371/journal.pone.0183315. eCollection 2017.
[h=1]Generation of a serum free CHO DG44 cell line stably producing a broadly protective anti-influenza virus monoclonal antibody.[/h] Chromikova V[SUP]1[/SUP], Zaragoza MA[SUP]1,[/SUP][SUP]2[/SUP], Krammer F[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Because of the broad neutralization and in vivo protection across influenza A and influenza B virus strains, monoclonal antibody CR9114 is widely used in influenza virus research as a positive control in many experiments. To produce amounts sufficient for the demand requires regular transient transfections, resulting in varying yield as well as differing batch to batch quality. Here, we report the development of a serum-free CHO DG44 cell line, stably producing a CR9114-like antibody with a potential to become a useful influenza virus research tool.
PMID: 28910287 DOI: 10.1371/journal.pone.0183315
[h=1]Generation of a serum free CHO DG44 cell line stably producing a broadly protective anti-influenza virus monoclonal antibody.[/h] Chromikova V[SUP]1[/SUP], Zaragoza MA[SUP]1,[/SUP][SUP]2[/SUP], Krammer F[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Because of the broad neutralization and in vivo protection across influenza A and influenza B virus strains, monoclonal antibody CR9114 is widely used in influenza virus research as a positive control in many experiments. To produce amounts sufficient for the demand requires regular transient transfections, resulting in varying yield as well as differing batch to batch quality. Here, we report the development of a serum-free CHO DG44 cell line, stably producing a CR9114-like antibody with a potential to become a useful influenza virus research tool.
PMID: 28910287 DOI: 10.1371/journal.pone.0183315